| 主权项 |
1. A method of treating Friedreich's ataxia in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of a polycyclic compound or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof;
wherein the polycyclic compound is of a formula: wherein: X is a linking group selected from the group consisting of —S(O)2— and —C(O)—; R1a and R1b are each independently selected from the group consisting of hydrogen, lower alkyl, fluoroalkyl, aryl, and heteroaryl; wherein the aryl or heteroaryl group has from 0 to 3 R4 substituents; R2 is a first cyclic group selected from the group consisting of phenyl, naphthyl, and heteroaryl; wherein the R2 group has from 0 to 3 R4 substituents; R3 is a second cyclic group selected from the group consisting of phenyl, naphthyl, and heteroaryl; wherein the R3 group has from 0 to 4 R4 substituents; each R4 substituent is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halo, —NO2, —CF3, —CN, —OR5, —SR5, —C(O)R5, —NHC(O)R5, —C(O)OR5, —OC(O)R5, —NR5R6, —C(O)NR5R6, —NHR5C(O)NR6R7, —S(O)2NR5R6, and a cyclic R4 substituent; wherein the cyclic R4 substituent is selected from the group consisting of aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, and heterocyclyl; and wherein the cyclic R4 substituent has from 0 to 3 R8 substituents; each R5, R6, or R7 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halo, or a cyclic R5 substituent; wherein the cyclic R5 substituent is selected from the group consisting of aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, and heterocyclyl; and wherein the cyclic R5 substituent has from 0 to 3 R8 substituents; and each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, or heterocyclyl; and wherein adjacent R4, R5, R6, or R7 substituents may optionally join to form an additional fused ring selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocyclyl; wherein the additional fused ring has from 0 to 3 R8 substituents; with the proviso that the polycyclic compound is not disclosed in U.S. Pat. No. 8,703,749. |
